7 completed, 3 recruiting, 2 not yet recruiting, 2 terminated. 5 Phase 4, 3 Not applicable, 3 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 5 | Completed 2, Recruiting 2, Terminated 1 |
| Not applicable | 3 | Completed 2, Withdrawn 1 |
| Phase 2 | 3 | Not yet recruiting 2, Completed 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Recruiting 1 |
Follow Plasmodium Vivax Malaria: new trials by email Literature Review of Plasmodium Vivax Malaria trials Research Report on Plasmodium Vivax Malaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tafenoquine Drug Levels in Small Children Chloroquine, Tafenoquine - Plasmodium Vivax Malaria, Vivax Malaria | Phase 2 | Not yet recruiting | University of Oxford | 20 | 2026-09-01 | 2026-09-22 |
| Phase IIa/b Trial of PvCS/Montanide ISA-51 Malaria Vaccine in Adults in Chocó, Colombia PvCS/Montanide ISA-51 VG Vaccine, Placebo - Montanide ISA-51 VG Adjuvant Alone - Plasmodium Vivax Malaria, Plasmodium Vivax Infection | Phase 2 | Not yet recruiting | Malaria Vaccine and Drug Development Center | 72 | 2026-01-19 | 2026-01-28 |
| Vivax Elimination With Tafenoquine (VET) Study Tafenoquine - Malaria, Malaria, Vivax | Phase 4 | Completed | Shoklo Malaria Research Unit | 1242 | 2025-02-19 | 2026-01-06 |
| FocaL Mass Drug Administration for Vivax Malaria Elimination Focal Mass Drug Administration (fMDA) - Plasmodium Vivax Malaria, Malaria | Phase 3 | Recruiting | University of California, San Francisco | 7530 | 2024-10-14 | 2026-06-09 |
| Southeast Asia Dose Optimization of Tafenoquine Tafenoquine, Chloroquine, Artemether 20 mg-Lumefantrine 120 mg - Plasmodium Vivax Malaria | Phase 4 | Recruiting | University of Oxford | 820 | 2024-07-22 | 2026-10-09 |
| ACT vs CQ With Tafenoquine for P. Vivax Mono-infection Dihydroartemisinin-piperaquine plus tafenoquine (450 mg adult dose), Chloroquine plus Tafenoquine (450 mg adult dose), Artemether-Lumefantrine plus Tafenoquine (450 mg adult dose) - Malaria, Malaria, Vivax | Phase 4 | Recruiting | Shoklo Malaria Research Unit | 606 | 2023-06-26 | 2025-05-16 |
| Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand Case Management and Follow-up, Reactive focal mass drug administration (rfMDA) - Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria | Not applicable | Completed | University of California, San Francisco | 14977 | 2020-11-01 | 2026-04-29 |
| Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Republic Household Reactive Case Detection, RACD of cases' co-workers/co-travelers, Case Management and Follow-up - Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria | Not applicable | Withdrawn | University of California, San Francisco | 2020-09-20 | 2026-04-29 | |
| DSM265 Phase IIa Investigation Treating Plasmodium Falciparum or Vivax DSM265 400mg, DSM265 xmg, DSM265 ymg - Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria | Phase 2 | Completed | Medicines for Malaria Venture | 45 | 2016-01-01 | 2016-06-22 |
| Malaria in Early Life Study dihydroartemisinin-piperaquine - Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria | Not applicable | Completed | Gadjah Mada University | 757 | 2014-07-21 | 2018-08-02 |
| Antimalarial Drug Susceptibility and Molecular Characterization of Plasmodium Vivax Isolates in Vietnam Chloroquine, Dihydroartemisinin/Piperaquine - Plasmodium Vivax Malaria | Phase 4 | Completed | Oxford University Clinical Research Unit, Vietnam | 330 | 2013-02-01 | 2016-09-30 |
| Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Vivax in Pregnancy in Brazil (PAACT-PV) Mefloquine- Artesunate, Artemether-Lumefantrine, Chloroquine - Plasmodium Vivax Malaria | Phase 4 | Terminated | Centers for Disease Control and Prevention | 16 | 2011-02-01 | 2012-04-13 |
| Clinical Trial for the Development of a Safe Malaria Challenge Model That Can be Reproduced in Humans Malaria Challenge - Plasmodium Vivax Malaria | Phase 1 | Completed | U.S. Army Medical Research and Development Command | 12 | 2009-04-21 | 2018-08-16 |
| PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria PpPfs25/ISA51 & ScPvs25/ISA51 - Plasmodium Falciparum, Plasmodium Vivax Malaria | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-03-07 | 2017-07-02 | |
| Papua New Guinean Duffy Negativity And Vivax Malar Plasmodium Vivax Malaria | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 266 | 2004-02-10 | 2019-02-04 |
Malaria, Vivax (15) · Malaria (7) · Malaria, Falciparum (5) · Parasitic Diseases (1) · Recurrence (1)
Infections (15) · Mosquito-Borne Diseases (15) · Protozoan Infections (15) · Vector Borne Diseases (15) · Parasitic Diseases (14) · Malaria (8) · Disease Attributes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Chloroquine (5) · tafenoquine (4) · Artemether, Lumefantrine Drug Combination (2) · Case Management (2) · artenimol (2) · piperaquine (2) · Artemether (1) · DSM265 (1) · Lumefantrine (1) · Primaquine (1) · lactitol (1)
University of California, San Francisco (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Shoklo Malaria Research Unit (2) · University of Oxford (2) · Centers for Disease Control and Prevention (1) · Gadjah Mada University (1) · Malaria Vaccine and Drug Development Center (1) · Medicines for Malaria Venture (1) · Oxford University Clinical Research Unit, Vietnam (1) · U.S. Army Medical Research and Development Command (1)
Thailand (5) · Vietnam (3) · Indonesia (2) · Laos (2) · Peru (2) · United States (2) · Brazil (1) · Cambodia (1) · Colombia (1) · Papua New Guinea (1)
Adam Bennett, MA, PhD (2) · Cindy Chu, MD, PhD (2) · Alejandro Llanos, Professor (1) · Alejandro Llanos-Cuentas, MD, PhD (1) · Cheewanan Lertpiriyasuwat, MD (1) · Francois Nosten, Prof (1) · Ilin Chuang, MD, MPH (1) · Jeanne R Poespoprodjo, MD, MSc, PhD (1) · Meghna Desai, MPH PhD (1) · Michelle Hsiang, MD (1) · Myriam Arevalo, PhD (1) · Viengxay Vanisaveth, MD (1)
PMID 18612426, PMID 22531245, PMID 23212366, PMID 29398388, PMID 29909069, PMID 30698522, PMID 35672703, PMID 40321759, PMID 41088393
U01AI157962 (1), U01AI195203 (1)